Harrow (HROW) News Today $39.42 -0.03 (-0.08%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$39.90 +0.48 (+1.23%) As of 09/12/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Harrow Down Today?Toggle Visibility of Why Is Harrow Down Today?Harrow, Inc. (NASDAQ:HROW) shares have slightly decreased today amid a mix of bullish growth drivers and mixed analyst revisions. Below are recent updates that may influence investor sentiment: Positive Sentiment: Bullish Seeking Alpha analysis highlights the VEVYE Access for All program, noting a 66% QoQ surge in prescriptions, robust 43.7% YoY revenue growth and an outlook for sustained momentum toward profitability. Harrow: Buy A Blend Of Value And Growth Positive Sentiment: William Blair upgraded its Q4 2025 EPS forecast to $0.36 from $0.07, reflecting stronger-than-expected seasonal performance. William Blair Research Positive Sentiment: William Blair maintains an “Outperform” rating and projects a robust Q4 2026 EPS of $0.76, signaling confidence in Harrow’s long-term earnings trajectory. William Blair Research Neutral Sentiment: Harrow launched a $250 million senior notes offering to refinance existing debt, potentially lowering interest costs and extending maturities. Harrow (HROW) Launches US$250M Senior Notes Offering To Refinance Debt Neutral Sentiment: American Banking News reviewed Harrow alongside Ernexa Therapeutics, offering comparative valuation and pipeline insights. Reviewing Harrow (NASDAQ:HROW) and Ernexa Therapeutics Neutral Sentiment: American Banking News also included Harrow in a sector review with Miravant Medical Technologies, highlighting differing growth profiles. Reviewing Miravant Medical Technologies (OTCMKTS:MRVT) and Harrow Negative Sentiment: William Blair trimmed its Q3 2025 EPS estimate to $0.07 from $0.13, signaling lower near-term growth expectations. William Blair Research Posted 1+ days agoAI Generated. May Contain Errors. HROW Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period William Blair Analysts Lower Earnings Estimates for HarrowSeptember 13 at 7:21 AM | marketbeat.comWilliam Blair Issues Negative Estimate for Harrow EarningsSeptember 13 at 2:05 AM | americanbankingnews.comHarrow Health Completes $250M Senior Notes SaleSeptember 12 at 5:30 PM | tipranks.comHarrow: Buy A Blend Of Value And GrowthSeptember 12 at 12:01 PM | seekingalpha.comTrexquant Investment LP Sells 84,853 Shares of Harrow, Inc. $HROWSeptember 12 at 3:21 AM | marketbeat.comReviewing Harrow (NASDAQ:HROW) and Ernexa Therapeutics (NASDAQ:ERNA)September 11 at 3:47 AM | americanbankingnews.comReviewing Miravant Medical Technologies (OTCMKTS:MRVT) and Harrow (NASDAQ:HROW)September 11 at 3:47 AM | americanbankingnews.comHarrow (HROW) Launches US$250M Senior Notes Offering To Refinance DebtSeptember 11 at 2:10 AM | finance.yahoo.comHarrow (NASDAQ:HROW) Shares Gap Up - Here's WhySeptember 10 at 1:53 PM | marketbeat.comHarrow: A Classical GARP StockSeptember 9, 2025 | seekingalpha.comHarrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030September 8, 2025 | globenewswire.comHarrow launches $250M debt offeringSeptember 8, 2025 | msn.comHarrow Health Launches $250 Million Senior Notes OfferingSeptember 8, 2025 | msn.comHarrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030September 8, 2025 | globenewswire.comAmerican Century Companies Inc. Purchases 18,142 Shares of Harrow, Inc. $HROWSeptember 6, 2025 | marketbeat.comHarrow Health’s Earnings Call Highlights Growth and ChallengesSeptember 5, 2025 | theglobeandmail.comHarrow, Inc. $HROW Shares Acquired by Braidwell LPSeptember 3, 2025 | marketbeat.comHarrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and EyleaSeptember 2, 2025 | finance.yahoo.comWellington Management Group LLP Sells 16,489 Shares of Harrow, Inc. $HROWSeptember 2, 2025 | marketbeat.comNuveen LLC Invests $2.05 Million in Harrow, Inc. $HROWSeptember 1, 2025 | marketbeat.comHarrow, Inc. (NASDAQ:HROW) Given Consensus Rating of "Buy" by BrokeragesAugust 28, 2025 | marketbeat.comHarrow: Few Hits Carrying Misses (Rating Downgrade)August 26, 2025 | seekingalpha.comPale Fire Capital SE Purchases New Shares in Harrow, Inc. $HROWAugust 26, 2025 | marketbeat.comHarrow, Inc. (HROW): A Bull Case TheoryAugust 26, 2025 | finance.yahoo.comHarrow, Inc. (HROW): A Bull Case TheoryAugust 26, 2025 | insidermonkey.comB. Riley Has Bullish Outlook for Harrow FY2025 EarningsAugust 26, 2025 | marketbeat.comHarrow announces leadership changes, Andrew Boll to serve as President and CFOAugust 25, 2025 | msn.comHarrow Health Appoints New President and CFOAugust 25, 2025 | tipranks.comB. Riley Analysts Raise Earnings Estimates for HarrowAugust 24, 2025 | marketbeat.comFox Run Management L.L.C. Takes Position in Harrow, Inc. $HROWAugust 22, 2025 | marketbeat.comFY2025 Earnings Forecast for Harrow Issued By HC WainwrightAugust 19, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 61,794 Shares of Harrow, Inc. (NASDAQ:HROW)August 18, 2025 | marketbeat.comHarrow (NASDAQ:HROW) Stock Price Down 4.9% - What's Next?August 17, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. ...August 17, 2025 | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROWAugust 17, 2025 | globenewswire.comHC Wainwright Issues Optimistic Forecast for Harrow EarningsAugust 17, 2025 | marketbeat.comWilliam Blair Has Positive Outlook for Harrow Q3 EarningsAugust 17, 2025 | marketbeat.comHarrow (NASDAQ:HROW) Trading 3.9% Higher - Here's WhyAugust 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROWAugust 16, 2025 | gurufocus.comCantor Fitzgerald Predicts Increased Earnings for HarrowAugust 16, 2025 | marketbeat.comEquities Analysts Issue Forecasts for Harrow Q1 EarningsAugust 16, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROWAugust 16, 2025 | prnewswire.comBTIG Research Forecasts Strong Price Appreciation for Harrow (NASDAQ:HROW) StockAugust 16, 2025 | marketbeat.comHarrow's Ambitious Guidance Puts It In The Proving GroundAugust 14, 2025 | seekingalpha.comHarrow Unusual Options ActivityAugust 14, 2025 | benzinga.comIBD Rating Upgrades: Harrow Flashes Improved Relative Price StrengthAugust 14, 2025 | msn.comHarrow: Exciting Times In StoreAugust 13, 2025 | seekingalpha.comHarrow price target raised to $64 from $60 at H.C. WainwrightAugust 13, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROWAugust 13, 2025 | globenewswire.comHarrow (NASDAQ:HROW) Posts Earnings Results, Beats Estimates By $0.23 EPSAugust 12, 2025 | marketbeat.com Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HROW Media Mentions By Week HROW Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HROW News Sentiment▼0.670.92▲Average Medical News Sentiment HROW News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HROW Articles This Week▼216▲HROW Articles Average Week Get the Latest News and Ratings for HROW and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Harrow and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TG Therapeutics News Merus News CRISPR Therapeutics News PTC Therapeutics News Krystal Biotech News Vaxcyte News ACADIA Pharmaceuticals News Arcellx News ADMA Biologics News Arrowhead Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HROW) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
